En zo zit het werkelijk:
We saw that especially the ad hoc supplies that we have to divide that we have to provide for various EU markets as a result of temporary shortages of competitive plasma derived product has been putting pressure on our planning to supply the European markets. And as we concurrently sell more than we can release, we foresee for the coming -- for the remainder of 2019 that we have some pressure on inventories especially here with regards to the European markets because of the -- of what I just told you about the fact that we were confronted with these unexpected demands in the European markets.
So, we will, however, be able to produce sufficient Ruconest to eliminate any supply pressure, once approved, once the second site is approved either by one of the main regulators, EMA or FDA, and we anticipate to have that in-hand by Q1 2020. Also, we are already currently processing the milk from that new facility under current, such that you will be having inventory ready by the time the facility is approved.